Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 18/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643624 | 0.81 | GCK (0.74) | GCKKDM4ELMNASMN1; SMN2 | |
| SCHEMBL2642521 | 0.80 | GCK (0.73) | GCKKDM4ELMNASMN1; SMN2 | |
| SCHEMBL14430975 | 0.77 | GCK (0.61) | GCKLMNA | |
| SCHEMBL14430973 | 0.77 | GCK (0.60) | GCKKDM4ELMNASMN1; SMN2 | |
| SCHEMBL2642304 | 0.76 | GCK (0.59) | GCKKDM4ELMNASMN1; SMN2 | |
| SCHEMBL2643522 | 0.73 | GCK (0.84) | GCK | |
| SCHEMBL2643497 | 0.72 | GCK (1.00) | GCK | |
| SCHEMBL2642942 | 0.72 | GCK (0.82) | GCK | |
| SCHEMBL2642904 | 0.71 | GCK (0.80) | GCKKDM4E | |
| SCHEMBL2643117 | 0.70 | GCK (1.00) | GCKKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496052-B1 | NOVEL AMINOBENZAMIDE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-7253188-B2 | Aminobenzamide derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-7253188-B2 | Aminobenzamide derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-7253188-B2 | Aminobenzamide derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-20050282815-A1 | Novel aminobenzamide derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1496052-A1 | NOVEL AMINOBENZAMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282815-A1 | Novel aminobenzamide derivative | GCKR, GCK, HK2 | GCK 2/4885CYP1A2 2944/4885CYP3A4 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.